文献速递肝肾功能剂量调整抗栓抗凝管理特殊人群用药

艾多沙班在非瓣膜性房颤合并急性心衰患者中的血药浓度与药效学研究

Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure.
PubMed 文献 · Clin Pharmacokinet · 2021-03-30

本研究评估了艾多沙班在非瓣膜性房颤(NVAF)合并急性心衰(AHF)住院患者中的药代动力学、药效学及安全性。结果显示谷浓度从第2天起保持稳定,肌酐清除率≤50mL/min者谷浓度更高,凝血标志物中位数维持在正常范围,无停药或严重不良事件,提示在指导剂量调整下艾多沙班抗凝治疗安全适当。

要点

  • 艾多沙班谷浓度从住院第2天起保持稳定,第1天因末次给药间隔差异变异较大。
  • 肌酐清除率≤50mL/min的患者谷浓度更高,应遵循剂量调整标准。
  • 凝血标志物F1+2和D-二聚体中位数在整个研究期间维持正常范围。

核心结论

  • 在NVAF合并AHF住院患者中,艾多沙班的药代动力学和药效学特征保持恒定。
  • 即使在此类患者中,经指导剂量调整的艾多沙班抗凝治疗被认为是安全适当的干预。
  • 肌酐清除率降低的患者应遵守剂量调整标准。

研究设计与样本

  • 患者接受艾多沙班60mg(需调整剂量时30mg),住院后连续7天及出院日于口服给药前采集血样。
  • 测定艾多沙班谷浓度及凝血标志物凝血酶原片段1和2(F1+2)与D-二聚体。
  • 平均观察期为13天(范围7-46天)。

主要发现

  • 艾多沙班谷浓度从第2天起保持恒定;第1天因末次给药与采血间隔不同变异较大。
  • 肌酐清除率≤50mL/min的患者谷浓度更高。
  • F1+2和D-二聚体中位数在整个研究期间维持在正常范围内。
  • 无药物停用,无严重不良事件报告。

关键数值与推荐

  • 艾多沙班给药剂量为60mg,需剂量调整时使用30mg。
  • 肌酐清除率≤50mL/min的患者谷浓度更高,应遵循剂量调整标准。

临床怎么用

  • 在NVAF合并AHF住院患者中,可按指导进行艾多沙班剂量调整并维持抗凝治疗。
  • 对肌酐清除率≤50mL/min的患者应特别注意遵守剂量调整标准。
  • 住院期间艾多沙班谷浓度从第2天起稳定,提示无需因急性心衰住院而常规频繁调整剂量。

局限性

  • 第1天谷浓度变异较大,与末次给药和采血间隔差异有关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to assess the pharmacokinetic and pharmacodynamic profiles and safety of edoxaban in patients with nonvalvular atrial fibrillation (NVAF) who were hospitalized with acute heart failure (AHF). METHODS: The trough plasma concentrations of edoxaban, and the coagulation biomarkers prothrombin fragments 1 and 2 (F1+2) and D-dimer, were determined. Twenty-six patients received edoxaban 60 mg (30 mg when dose adjustment was required) and blood samples were collected immediately before oral edoxaban administration for 7 consecutive days after hospitalization and on the day of discharge. RESULTS: The mean observation period was 13 (range 7-46) days. Trough plasma concentrations of edoxaban were constant from day 2 onwards. On day 1, the variation was greater owing to the differing intervals between the last edoxaban dose and day 1 blood collection. Trough plasma concentrations were higher in patients with reduced creatinine clearance (≤ 50 mL/min). Median values for F1+2 and D-dimer remained within normal ranges throughout the study. There were no drug discontinuations, and no serious adverse events were reported. CONCLUSIONS: This is the first study of edoxaban pharmacokinetics and pharmacodynamics in patients with NVAF and AHF, and shows that the pharmacokinetic and pharmacodynamic profiles of edoxaban were constant during hospitalization. Thus, even in patients with NVAF and AHF, edoxaban anticoagulation therapy with guided dose adjustment is considered to be a safe and appropriate intervention. In particular, patients with reduced creatinine clearance should adhere to dose adjustment criteria. CLINICAL TRIAL REGISTRATION: jRCTs031190006 (Japan Registry of Clinical Trials), 5 April, 2019 retrospectively registered.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Nabeta T, Kida K, Ishida M, et al. Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure. Clin Pharmacokinet. 2021. PMID: 33782831. doi:10.1007/s40262-021-00999-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。